Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kobayashi Pharm. to Create 3 Subsidiaries in Southeast Asia
November 8, 2011
- Takeda Establishes New Positions in R&D, Global Sales
November 7, 2011
- Takeda Reinstates Request for Probe into Transfer Pricing Taxation
November 7, 2011
- Takeda: Sales, Profits Down due to Strong Yen, Double-digit Decreases in Sales of Actos in Apr-Sep
November 7, 2011
- Suzuken Reports Largest Interim Operating Loss From Drug Wholesale Business
November 7, 2011
- Operating Profits Down 70% in Wholesale Business: Alfresa HD
November 7, 2011
- 8 of 10 Leading Drug Makers Report Declines in 1st-Half Sales
November 7, 2011
- Takeda President Hasegawa Plans to Complete Integration with Nycomed in 3 Years
November 7, 2011
- Ono: Glactiv, Emend Drive Growth in 1st-Half Sales
November 7, 2011
- Astellas President Hatanaka Says Company Can Continue on Growth Path Through 2014
November 7, 2011
- Kissei: Pharm. Sales Down 0.5%, Profits Up
November 7, 2011
- ASKA: Sales Down 8.4% Due to Rebound from a Spike at Last Fiscal Year End
November 7, 2011
- Breast Cancer Project Selected for Health Science Research Grant: 3-D Matrix
November 7, 2011
- Pharmacies Satisfied, Wholesalers Dissatisfied with Price Negotiations: Yano Research Survey
November 7, 2011
- CMIC: Sales, Profits Up Driven by CRO Business
November 7, 2011
- Kawasumi Lab.: Declines in Sales, Profits
November 7, 2011
- Takara Bio: Research Reagents Drive Growth in Sales, Profits
November 7, 2011
- Sales of Actos Down 22% in 1st Half Due to Bladder Cancer Concerns, Generic Competition: Takeda
November 5, 2011
- Qol Decides to Discontinue “Dispensing Points” in March 2012
November 4, 2011
- Ono President Says Glactiv to “Still Show Advantage of Early Release”
November 4, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…